Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Rafael Holdings, Inc. (RFL)

$2.13 +1.91% NYSE: RFL · 15-min delayed
  • NEWARK, New Jersey
  • Public · NYSE: RFL
  • 23 employees
$80.6MMarket cap
$30.0KRevenue · FY2025
-$30.5MNet income
23Employees
RFLNYSE
2018IPO

About Rafael Holdings, Inc.

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$30.0K
Net income
-$30.5M
Total assets
$114.1M
Market cap
$80.6M
Operating margin
-3179.8%
Net margin
-3341.7%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$917.0K
Operating expenses
$30.1M
Operating income
-$29.2M
Income tax
-$2.6M
Net income
-$30.6M
EPS (basic)
$-1.04
EPS (diluted)
$-1.04

Balance sheet

Total assets
$114.1M
Current assets
$56.7M
Total liabilities
$15.7M
Current liabilities
$11.6M
Shareholders’ equity
$98.4M

Cash flow

Operating cash flow
-$18.9M
Investing cash flow
$44.0M
Financing cash flow
$24.8M
Net cash flow
$50.1M

Statements via Polygon.io (SEC filings)

NYSE: RFL
$2.13 +1.91%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.16 $3.78

52-week range

Market cap
$80.6M
EPS (diluted)
$-1.04
Dividend yield
3.8%
Shares outstanding
37.8M
Open
Day range
Prev close
Volume
IPO date
Mar 6, 2018

Rafael Holdings, Inc. (RFL) Stock Price

  • Reported a net loss of $30.5M in FY2025.
  • Revenue declined 77% from FY2021 to FY2025.
  • Trading 44% below its 52-week high.
  • Pays a dividend yielding about 3.8% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Rafael Holdings, Inc..

Write a review
Newsroom

News about Rafael Holdings, Inc.

News & sentiment via Polygon.io

FAQ

Rafael Holdings, Inc.: frequently asked questions

Is Rafael Holdings, Inc. an American company?

Rafael Holdings, Inc. is a US-based company headquartered in Newark, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Rafael Holdings, Inc. headquartered?

Rafael Holdings, Inc. is headquartered in Newark, New Jersey, United States.

Is Rafael Holdings, Inc. publicly traded?

Yes — Rafael Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol RFL on the NYSE.

What does Rafael Holdings, Inc. do?

Rafael Holdings, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →